Latest Tyrosine kinase inhibitors Stories
Almost twelve million -- that’s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It’s a problem researchers at Case Western Reserve University are working to better understand.
A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening.
Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy.